Neurocysticercosis

 

 Buy Article Permissions and Reprints

ABSTRACT

Neurocysticercosis is the most common helminthic disease of the nervous system and currently represents a major public health problem in developing countries of Latin America, Asia, and Africa, as well as in industrialized nations with a high immigration rate of people from endemic areas. The disease occurs when humans become the intermediate host in the life cycle of Taenia solium by ingesting its eggs from contaminated food. Neurocysticercosis is pleomorphic in its presentation due to individual differences in the number, size, and location of the parasites, as well as differences in the severity of the host's immune reaction to the parasite. Epilepsy, focal neurological signs, and intracranial hypertension are the most common clinical manifestations of the disease. The diagnosis of neurocysticercosis is based on clinical data, neuroimaging abnormalities, and the results of immunological tests. Two drugs, albendazole and praziquantel, are cysticidal and destroy most intracranial parasites; however, surgery may be necessary in the management of some forms of the disease, particularly hydrocephalus and intraventricular cysts. Although the development of modern diagnostic tests and the introduction of potent cestocidal drugs have increased our ability to make the diagnosis of neurocysticercosis and improved prognosis, some patients still have a torpid clinical course despite prompt diagnosis and proper therapy.

REFERENCES

• 1 García H H, Gonzalez A E, Evans C AW, Gilman R H. Taenia solium cysticercosis.  Lancet. 2003;  362 547-556
  CrossrefPubMedGoogle Scholar
• 2 Ong S, Talan D A, Moran G J et al.. Neurocysticercosis in radiographically imaged seizure patients in U.S. emergency departments.  Emerg Infect Dis. 2002;  8 608-613
  CrossrefPubMedGoogle Scholar
• 3 Sotelo J. Neurocysticercosis: eradication of cysticercosis is an attainable goal.  BMJ. 2003;  326 511-512
  CrossrefPubMedGoogle Scholar
• 4 Román G, Sotelo J, Del Brutto O H et al.. A proposal to declare neurocysticercosis an international reportable disease.  Bull World Health Organ. 2000;  78 399-406
  PubMedGoogle Scholar
• 5 Del Brutto O H, Sotelo J, Román G C. Neurocysticercosis: A Clinical Handbook. Lisse, The Netherlands; Swets & Zeitlinger 1998
  Google Scholar
• 6 Pittella J EH. Neurocysticercosis.  Brain Pathol. 1997;  7 681-693
  CrossrefPubMedGoogle Scholar
• 7 Escobar A, Weidenheim K M. The pathology of neurocysticercosis. In: Singh G, Prabhakar S Taenia Solium Cysticercosis: From Basic to Clinical Science. Oxford, UK; CAB International 2002: 289-305
  Google Scholar
• 8 Del Brutto O H. Cysticercosis and cerebrovascular disease: a review.  J Neurol Neurosurg Psychiatry. 1992;  55 252-254
  CrossrefPubMedGoogle Scholar
• 9 Del Brutto O H, Santibañez R, Noboa C A, Aguirre R, Díaz E, Alarcón T A. Epilepsy due to neurocysticercosis: analysis of 203 patients.  Neurology. 1992;  42 389-392
  CrossrefPubMedGoogle Scholar
• 10 Estañol B, Kleriga E, Loyo M et al.. Mechanisms of hydrocephalus in cerebral cysticercosis: implications for therapy.  Neurosurgery. 1983;  13 119-123
  PubMedGoogle Scholar
• 11 Noboa C A. Encefalitis cisticercosa.  Rev Ecuat Neurol. 1992;  1 61-71
  PubMedGoogle Scholar
• 12 Singh G, Sawhney I S. Taenia solium cysticercosis: uncommon manifestations. In: Singh G, Prabhakar S Taenia Solium Cysticercosis: From Basic to Clinical Science. Oxford, UK; CAB International 2002: 229-239
  Google Scholar
• 13 Sawhney B B, Chopra J S, Banerji A K, Wahi P L. Pseudohypertrophic myopathy in cysticercosis.  Neurology. 1976;  26 270-272
  PubMedGoogle Scholar
• 14 García H H, Del Brutto O H. Imaging findings in neurocysticercosis.  Acta Trop. 2003;  87 71-78
  PubMedGoogle Scholar
• 15 Ordoñez G, Medina M T, Sotelo J. Immunoblot analysis of serum and CSF from patients with various forms of neurocysticercosis.  Neurol Infect Epidemiol. 1996;  1 57-61
  PubMedGoogle Scholar
• 16 Del Brutto O H, Rajshekhar V, White Jr A C et al.. Proposed diagnostic criteria for neurocysticercosis.  Neurology. 2001;  57 177-183
  CrossrefPubMedGoogle Scholar
• 17 Del Brutto O H, Sotelo J, Roman G C. Therapy for neurocysticercosis: a reappraisal.  Clin Infect Dis. 1993;  17 730-735
  CrossrefPubMedGoogle Scholar
• 18 García H H, Evans C AW, Nash T E et al.. Current consensus guidelines for treatment of neurocysticercosis.  Clin Microbiol Rev. 2002;  15 747-756
  CrossrefPubMedGoogle Scholar
• 19 Sotelo J, Del Brutto O H, Penagos P et al.. Comparison of therapeutic regimen of anticysticercal drugs for parenchymal brain cysticercosis.  J Neurol. 1990;  237 69-72
  CrossrefPubMedGoogle Scholar
• 20 Takayanagui O M, Jardim E. Therapy for neurocysticercosis: comparison between albendazole and praziquantel.  Arch Neurol. 1992;  49 290-294
  CrossrefPubMedGoogle Scholar
• 21 Singhi P, Dayal D, Khandelwal N. One week versus four weeks of albendazole therapy for neurocysticercosis in children: a randomized, placebo-controlled double blind trial.  Pediatr Infect Dis J. 2003;  22 268-272
  CrossrefPubMedGoogle Scholar
• 22 Garcia H H, Pretell E J, Gilman R H et al.. A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis.  N Engl J Med. 2004;  350 249-258
  CrossrefPubMedGoogle Scholar
• 23 Bittencourt P RM, Gracia C M, Gorz A M, Mazer S, Oliveira T V. High-dose praziquantel for neurocysticercosis: efficacy and tolerability.  Eur Neurol. 1990;  30 229-234
  CrossrefPubMedGoogle Scholar
• 24 Del Brutto O H, Campos X, Sánchez J, Mosquera A. Single-day praziquantel versus 1-week albendazole for neurocysticercosis.  Neurology. 1999;  52 1079-1081
  PubMedGoogle Scholar
• 25 Garcia H H, Gilman R H, Horton J et al.. Albendazole therapy for neurocysticercosis: a prospective double-blind trial comparing 7 versus 14 days of treatment.  Neurology. 1997;  48 1421-1427
  CrossrefPubMedGoogle Scholar
• 26 Proaño J V, Madrazo I, Avelar F, López-Félix B, Diaz G, Grijalva I. Medical treatment for neurocysticercosis characterized by giant subarachnoid cysts.  N Engl J Med. 2001;  345 879-885
  CrossrefPubMedGoogle Scholar
• 27 Del Brutto O H, Sotelo J, Aguirre R, Díaz-Calderón E, Alarcón T A. Albendazole therapy for giant subarachnoid cysticerci.  Arch Neurol. 1992;  49 535-538
  PubMedGoogle Scholar
• 28 Rajshekhar V. Solitary cerebral cysticercus granuloma.  Epilepsia. 2003;  44(suppl 1) 25-28
  PubMedGoogle Scholar
• 29 Del Brutto O H. The use of albendazole in patients with single lesions enhanced on contrast CT.  N Engl J Med. 1993;  328 356-357
  CrossrefPubMedGoogle Scholar
• 30 Del Brutto . OHPrognostic factors for seizure recurrence after withdrawal of antiepileptic drugs in patients with neurocysticercosis.  Neurology. 1994;  44 1706-1709
  PubMedGoogle Scholar
• 31 Sotelo J, Marin C. Hydrocephalus secondary to cysticercotic arachnoiditis: a long-term follow-up review of 92 cases.  J Neurosurg. 1987;  66 686-689
  CrossrefPubMedGoogle Scholar
• 32 Suastegui Roman R A, Soto-Hernández J L, Sotelo J. Effects of prednisone on ventriculoperitoneal shunt function in hydrocephalus secondary to cysticercosis: a preliminary study.  J Neurosurg. 1996;  84 629-633
  PubMedGoogle Scholar
• 33 Bergsneider M, Holly L T, Lee J H, King W A, Frazee J G. Endoscopic management of cysticercal cysts within the lateral and third ventricles.  J Neurosurg. 2000;  92 14-23
  Google Scholar

Oscar H Del BruttoM.D. 

Air Center, 3542, P.O. Box 522970

Miami, FL 33152-2970